Patent Assignment
Reel/Frame 027445/0100
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded: 2011-12-27
Received: 2011-12-27
Pages: 17
Assignor
WARNER CHILCOTT COMPANY, LLC
Executed: 2011-12-15
Assignee
AKEBIA THERAPEUTICS INC.
9987 CARVER ROAD, SUITE 420, CINCINNATI, OH, 45242, UNITED STATES
Covered Applications
(40)
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHOD OF USE
App. No. 13/309,445
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
App. No. 13/309,452
→
CRYSTAL OF HYPOXIA INDUCIBLE FACTOR 1 ALPHA PROLYL HYDROXYLASE
App. No. 13/230,548
→
METHOD FOR TREATING CORONARY ARTERY DISEASE USING ANTIBODY BINDING HUMAN PROTEIN TYROSINE PHOSPHATASE BETA(HPTPbeta)
App. No. 13/115,180
→
PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE
App. No. 12/860,136
→
PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE
App. No. 12/860,073
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
App. No. 12/850,026
→
N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES
App. No. 12/845,061
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
App. No. 12/624,072
→
HEPTbeta AS A TARGET IN TREATMENT OF ANGIOGENISIS MEDIATED DISORDERS
App. No. 12/610,843
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
App. No. 12/558,169
→
CRYSTAL OF HYPOXIA INDUCIBLE FACTOR 1 ALPHA PROLYL HYDROXYLASE
App. No. 12/473,536
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
App. No. 12/467,430
→
THREE DIMENSIONAL COORDINATES OF HPTPBETA
App. No. 12/409,111
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
PCTPCTUS2007014823
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
PCTPCTUS2007014824
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
PCTPCTUS2007014822
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AN METHODS OF USE
App. No. 11/823,086
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
App. No. 11/821,846
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
App. No. 11/821,868
→
PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE
App. No. 11/821,936
→
PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE
PCTPCTUS2007014832
→
N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES
App. No. 11/820,099
→
PHARMACEUTICAL COMPOSITIONS THAT MODULATE HPTPBETA ACTIVITY
App. No. 11/787,535
→
ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
App. No. 11/784,094
→
CRYSTAL OF HYPOXIA INDUCIBLE FACTOR 1 ALPHA PROLYL HYDROXYLASE
App. No. 11/713,941
→
Compounds which regulate angiogenesis
App. No. 60/816,731
→
Compounds which regulate angiogenes
App. No. 60/816,730
→
Compounds which regulate angiogenesis
App. No. 60/816,825
→
Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
App. No. 60/798,896
→
Monoclonal antibody phosphatase inhibitors for therapeutic angiogenesis
App. No. 60/790,506
→
N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES
App. No. 11/152,002
→
N-SULFONYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES
App. No. 11/151,897
→
N-SULFONYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES
App. No. 10/703,067
→
N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES
App. No. 10/702,953
→
HPTPBETA AS A TARGET IN TREATMENT OF ANGIOGENESIS MEDIATED DISORDERS
App. No. 10/633,742
→
THREE DIMENSIONAL COORDINATES OF HPTPBETA
App. No. 10/634,027
→
N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
App. No. 60/425,071
→
N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
App. No. 60/425,070
→
HPTPbeta as a target in treatment of angiogenesis mediated disorders
App. No. 60/413,547
→